Araştırma Makalesi
BibTex RIS Kaynak Göster

HEPATİT C TARAMASI İÇİN SADECE ANTİ-HCV TESTİ İSTEMEK YETERLİ MİDİR?

Yıl 2024, Cilt: 87 Sayı: 3, 215 - 219, 19.07.2024
https://doi.org/10.26650/IUITFD.1401786

Öz

Amaç: HCV enfeksiyonu, tedavi edilmediği sürece yüksek morbidite ve mortalite ile ilişkilidir. Bu çalışmada anti-HCV tarama etkinliği ve tedaviye erişim oranları araştırılmıştır.
Gereç ve Yöntem: Bu kesitsel çalışmada Ocak 2014 ile Haziran 2017 tarihleri arasında istenen tüm anti-HCV testleri hastane kayıtlarından tarandı. Hasta görüşmeleri yüz yüze veya telefon ortamında yapıldı.
Bulgular: İstenilen toplam anti-HCV testi sayısı 77783 olup, bunların 1373'ü pozitif çıkmıştır. Bunlardan 266'sı kadın, 222'si erkek; yaş ortalaması 52,81±16,5 yıl olan 488 hastayla görüşme yapılmıştır. Anti-HCV pozitif hastaların 69'una (%14,1) HCV-RNA ile ileri araştırma yapılmadığı saptandı. 309 hastada HCV-RNA pozitifti ve 268'i tedavi almışken (%86), 41'i (%14) tedavi edilmemişti. Tedavisiz kalmanın temel nedenleri ise bilinmeyen (%21), takip edilmeyen hasta (%28) ve hekimin endikasyon göstermemesi (%19) olarak belirlendi.
Sonuç: HCV'nin başarılı bir şekilde eradike edilmesi için anti-anti-HCV testi tek başına yeterli değildir. Hastaların anti-HCV testi sonuçları hakkında bilgilendirilmesi; pozitif ise HCV-RNA testine başvurulması önemlidir. Tedavi edilmeyen hasta sayısının yüksek olduğu göz önüne alındığında, mutlak bir kontrendikasyon olmadığı sürece HCV-RNA pozitif hastalarda tedaviye yönlendirilme teşvik edilmelidir.

Kaynakça

  • Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61(1 Suppl):S58-68. [CrossRef] google scholar
  • World Health Organization. Global hepatitis report 2017. Geneva SWhttps://www.who.int/publications/i/ item/9789241565455 . google scholar
  • Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146(5):1176-92. [CrossRef] google scholar
  • World Health Organization. Combating hepatitis B and C to reach elimination by 2030. 28 Feb 19. http://apps.who. int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_ eng.pdf?ua=1. google scholar
  • Idilman R, Razavi H, Robbins-Scott S, Akarca US, Örmeci N, Kaymakoglu S, et al. A micro-elimination approach to addressing hepatitis C in Turkey. BMC Health Serv Res 2020;20(1):249. [CrossRef] google scholar
  • Radwan D, Cachay E, Falade-Nwulia O, Moore R, Westergaard R, Mathews WC, et al. HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014-2015. J Acquir Immune Defic Syndr 2019;80(5):559-67. [CrossRef] google scholar
  • Naz A, Mukry SN, Naseer I, Shamsi TS. Evaluation of efficacy of serological methods for detection of HCV infection in blood donors: A single centre experience. Pak J Med Sci 2018;34(5):1204-8. [CrossRef] google scholar
  • Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015;21(11):1020-6. [CrossRef] google scholar
  • Bielen R, Kremer C, Koc OM, Busschots D, Hendrickx D, Vanelderen P, et al. Screening for hepatitis C at the emergency department: Should babyboomers also be screened in Belgium? Liver Int 2019;39(4):667-75. [CrossRef] google scholar
  • Orkin C, Leach E, Flanagan S, Wallis E, Ruf M, Foster GR, et al. High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees? Epidemiol Infect 2015;143(13):2837-40. [CrossRef] google scholar
  • Bert F, Rindermann A, Abdelfattah MA, Stahmeyer JT, Rossol S. High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area: a prospective survey including 10 215 patients of an interdisciplinary emergency unit. Eur J Gastroenterol Hepatol 2016;28(11):1246-52. [CrossRef] google scholar
  • Crowley D, Van Hout MC, Murphy C, Kelly E, Lambert JS, Cullen W. Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective-a qualitative exploration. Health Justice 2018;6(1):23. [CrossRef] google scholar
  • Buti M, Dominguez-Hernandez R, Casado MA, Sabater E, Esteban R. Healthcare value of implementing hepatitis C screening in the adult general population in Spain. PLoS One 2018;13(11):e0208036. [CrossRef] google scholar

IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?

Yıl 2024, Cilt: 87 Sayı: 3, 215 - 219, 19.07.2024
https://doi.org/10.26650/IUITFD.1401786

Öz

Objective: Unless treated, a hepatitis C virus (HCV) infection is associated with high morbidity and mortality. The study investigates anti-HCV screening efficacy and treatment access rates for patients.
Material and Method: This cross-sectional study screened all anti-HCV tests requested between January 2014-June 2017 from hospital records. Patient interviews were conducted by telephone-based interview.
Result: The overall number of anti-HCV tests requested was 77,783, 1,373 of which were positive. Among these, the study interviewed 488 patients (266 females, 222 males; mean age=52.81±16.5 years) and analyzed their tests. Further investigation with HCV-RNA had not been done in 69 (14.1%) anti-HCV positive patients. HCV-RNA was positive in 309 patients, 268 of whom were treated (86%), while 41 were not (14%). The main reasons for remaining untreated are: unknown (21%), no patient follow up (28%), or physician didn’t indicate (19%).
Conclusion: In order to successfully eliminate HCV, the anti-HCV test alone is not enough. Informing patients about the results of the anti-HCV test and, if positive, referring them for the HCV-RNA test are important. When considering the high amount of untreated patients, linkage to care should be encouraged in HCV-RNA positive patients unless an absolute contraindication is present.

Etik Beyan

The study protocol was approved by the Institutional Research Ethics Committee (Project number 2023/1662), and all patients gave a written informed consent.

Destekleyen Kurum

none

Teşekkür

none

Kaynakça

  • Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61(1 Suppl):S58-68. [CrossRef] google scholar
  • World Health Organization. Global hepatitis report 2017. Geneva SWhttps://www.who.int/publications/i/ item/9789241565455 . google scholar
  • Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146(5):1176-92. [CrossRef] google scholar
  • World Health Organization. Combating hepatitis B and C to reach elimination by 2030. 28 Feb 19. http://apps.who. int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_ eng.pdf?ua=1. google scholar
  • Idilman R, Razavi H, Robbins-Scott S, Akarca US, Örmeci N, Kaymakoglu S, et al. A micro-elimination approach to addressing hepatitis C in Turkey. BMC Health Serv Res 2020;20(1):249. [CrossRef] google scholar
  • Radwan D, Cachay E, Falade-Nwulia O, Moore R, Westergaard R, Mathews WC, et al. HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014-2015. J Acquir Immune Defic Syndr 2019;80(5):559-67. [CrossRef] google scholar
  • Naz A, Mukry SN, Naseer I, Shamsi TS. Evaluation of efficacy of serological methods for detection of HCV infection in blood donors: A single centre experience. Pak J Med Sci 2018;34(5):1204-8. [CrossRef] google scholar
  • Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015;21(11):1020-6. [CrossRef] google scholar
  • Bielen R, Kremer C, Koc OM, Busschots D, Hendrickx D, Vanelderen P, et al. Screening for hepatitis C at the emergency department: Should babyboomers also be screened in Belgium? Liver Int 2019;39(4):667-75. [CrossRef] google scholar
  • Orkin C, Leach E, Flanagan S, Wallis E, Ruf M, Foster GR, et al. High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees? Epidemiol Infect 2015;143(13):2837-40. [CrossRef] google scholar
  • Bert F, Rindermann A, Abdelfattah MA, Stahmeyer JT, Rossol S. High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area: a prospective survey including 10 215 patients of an interdisciplinary emergency unit. Eur J Gastroenterol Hepatol 2016;28(11):1246-52. [CrossRef] google scholar
  • Crowley D, Van Hout MC, Murphy C, Kelly E, Lambert JS, Cullen W. Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective-a qualitative exploration. Health Justice 2018;6(1):23. [CrossRef] google scholar
  • Buti M, Dominguez-Hernandez R, Casado MA, Sabater E, Esteban R. Healthcare value of implementing hepatitis C screening in the adult general population in Spain. PLoS One 2018;13(11):e0208036. [CrossRef] google scholar
Toplam 13 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Hizmetleri ve Sistemleri (Diğer)
Bölüm ARAŞTIRMA
Yazarlar

Rabia Deniz 0000-0003-4537-894X

Seda Karslı 0000-0003-0765-0770

Ömer Burak Ekinci

İlkana Kalantarova 0009-0007-4852-8532

Alp Atasoy 0000-0003-1791-897X

Mustafa Önel 0000-0002-3987-6611

Ali Ağaçfidan 0000-0002-5470-296X

Filiz Akyüz 0000-0001-7498-141X

Kadir Demir 0000-0002-5226-3705

Fatih Beşışık 0000-0001-5184-376X

Sabahattin Kaymakoğlu 0000-0003-4910-249X

Yayımlanma Tarihi 19 Temmuz 2024
Gönderilme Tarihi 13 Aralık 2023
Kabul Tarihi 22 Mart 2024
Yayımlandığı Sayı Yıl 2024 Cilt: 87 Sayı: 3

Kaynak Göster

APA Deniz, R., Karslı, S., Ekinci, Ö. B., Kalantarova, İ., vd. (2024). IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?. Journal of Istanbul Faculty of Medicine, 87(3), 215-219. https://doi.org/10.26650/IUITFD.1401786
AMA Deniz R, Karslı S, Ekinci ÖB, Kalantarova İ, Atasoy A, Önel M, Ağaçfidan A, Akyüz F, Demir K, Beşışık F, Kaymakoğlu S. IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?. İst Tıp Fak Derg. Temmuz 2024;87(3):215-219. doi:10.26650/IUITFD.1401786
Chicago Deniz, Rabia, Seda Karslı, Ömer Burak Ekinci, İlkana Kalantarova, Alp Atasoy, Mustafa Önel, Ali Ağaçfidan, Filiz Akyüz, Kadir Demir, Fatih Beşışık, ve Sabahattin Kaymakoğlu. “IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?”. Journal of Istanbul Faculty of Medicine 87, sy. 3 (Temmuz 2024): 215-19. https://doi.org/10.26650/IUITFD.1401786.
EndNote Deniz R, Karslı S, Ekinci ÖB, Kalantarova İ, Atasoy A, Önel M, Ağaçfidan A, Akyüz F, Demir K, Beşışık F, Kaymakoğlu S (01 Temmuz 2024) IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?. Journal of Istanbul Faculty of Medicine 87 3 215–219.
IEEE R. Deniz, “IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?”, İst Tıp Fak Derg, c. 87, sy. 3, ss. 215–219, 2024, doi: 10.26650/IUITFD.1401786.
ISNAD Deniz, Rabia vd. “IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?”. Journal of Istanbul Faculty of Medicine 87/3 (Temmuz 2024), 215-219. https://doi.org/10.26650/IUITFD.1401786.
JAMA Deniz R, Karslı S, Ekinci ÖB, Kalantarova İ, Atasoy A, Önel M, Ağaçfidan A, Akyüz F, Demir K, Beşışık F, Kaymakoğlu S. IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?. İst Tıp Fak Derg. 2024;87:215–219.
MLA Deniz, Rabia vd. “IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?”. Journal of Istanbul Faculty of Medicine, c. 87, sy. 3, 2024, ss. 215-9, doi:10.26650/IUITFD.1401786.
Vancouver Deniz R, Karslı S, Ekinci ÖB, Kalantarova İ, Atasoy A, Önel M, Ağaçfidan A, Akyüz F, Demir K, Beşışık F, Kaymakoğlu S. IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?. İst Tıp Fak Derg. 2024;87(3):215-9.

Contact information and address

Addressi: İ.Ü. İstanbul Tıp Fakültesi Dekanlığı, Turgut Özal Cad. 34093 Çapa, Fatih, İstanbul, TÜRKİYE

Email: itfdergisi@istanbul.edu.tr

Phone: +90 212 414 21 61